---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Care management intervention strategies"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Care management intervention strategies. Topics: Patient-reported outcome measures at every visit; Stepping treatment up or down: assess, act and adjust, and reassess; Omalizumab interval prolongation after 3 months of complete control; Omalizumab step-down: relapse after gradual de-escalation versus abrupt discontinuation, meta-analysis; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Patient-reported outcome measures at every visit

> “Patients should be assessed for disease activity, impact, and control at all visits.”
> “The UAS7, calculated as the sum of daily scores over 7 consecutive days, should be routinely used to monitor disease activity and treatment response in patients with CSU.”
> “It is important to highlight that patients need good counseling regarding continuous treatment and using PROMs, especially about using the UAS.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-2"></a>

### Stepping treatment up or down: assess, act and adjust, and reassess

> “Treatment should follow the basic principles of treating as much as needed and as little as possible, taking into consideration that the activity of the disease may vary”
> “This implies stepping up or stepping down in the treatment algorithm according to the course of disease following the principle assess, act & adjust, and reassess”
> “In order to constantly ensure the right level of treatment, patients need to be seen at regular intervals and adjustments are recommended based on the level of symptoms.”
> “For a stepdown, different options exist but costs are especially relevant for choosing which step to take first.”
> “In patients who are in the range of UCT 12–15, therefore a step up might also be required.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-3"></a>

### Omalizumab interval prolongation after 3 months of complete control

> “After 3 months of complete control, the interval can be prolonged until long as first wheals reappear, as there is no tachyphylaxis nor have relevant levels of blocking antibodies been described.”
> “But also, the prolongation of the interval is strictly off label.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.4-4"></a>

### Omalizumab step-down: relapse after gradual de-escalation versus abrupt discontinuation, meta-analysis

> “Random-effects proportion meta-analysis (DerSimonian-Laird logit transformation) determined pooled relapse rates.”
> “The overall pooled post-discontinuation relapse rate was 39.5% (95% CI: 30.1%-49.7%; I2 = 91.5%).”
> “Gradual de-escalation achieved a significantly lower pooled relapse rate compared with abrupt discontinuation (31.2% [95% CI: 20.3%-44.7%] vs. 48.9% [95% CI: 37.0%-61.0%], Qb = 8.12, df = 1, p = 0.004).”
> “Concomitant angioedema was an independent risk factor for relapse (multivariate OR = 2.399, p = 0.004), whereas gradual de-escalation was protective (multivariate OR = 0.373, p = 0.005).”

Source: [Doğan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42886609/)

<a id="topic-2.2.2.4-5"></a>

### Omalizumab cessation: pooled relapse across 41 stopping risk sets and uncertainty about stopping strategies

> “Forty-one stopping risk sets (2,643 patients; 1,209 source-reported events) yielded a pooled proportion of 46.6% (95% CI 40.1-53.2%; I2 = 87.7%; prediction interval 16.0-79.9%).”
> “Relapse is common after cessation, but high heterogeneity limits individualized prediction. The evidence cannot establish a causal advantage of any stopping strategy or an immune endotype for recurrence.”

Source: [Yücel and Ünal (2026)](https://pubmed.ncbi.nlm.nih.gov/43019004/)

<a id="topic-2.2.2.4-6"></a>

### Primary care: periodic antihistamine withdrawal to test for remission

> “Urticaria is a common condition presenting both as acute and chronic disease within primary care.”
> “However, when remission is achieved, therapy should be withdrawn every 3–6 months to discover whether natural remission has occurred.”

Source: [Ryan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9533216/)

<a id="topic-2.2.2.4-7"></a>

### Barzolvolimab phase 3b extension: observation of controlled disease and retreatment on flare

> “In addition, a global Phase 3b long term extension (LTE) study has been established for patient entry after completion of the EMBARQ - CSU Phase 3 trials.”
> “The study will consist of 2 Groups: Group 1 (Observation Group), containing patients whose disease remains well controlled (UAS7<16) and Group 2 (Barzolvolimab Retreatment Group) containing patients whose disease is currently moderate to severe (UAS7≥16).”
> “Patients in the observation group (Group 1) whose CSU flares to a UAS7>/=16 in the first 6 months of the LTE will also be able to receive treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.2.2.4-8"></a>

### Treatment escalation in practice: CURE registry

> “This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice.”
> “About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU.”
> “Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.”

Source: [Kolkhir et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466147/)

<a id="topic-2.2.2.4-9"></a>

### Mobile app symptom monitoring: adherence to CRUSE

> “We analysed data from 2085 patients (66,114 days). Median adherence to the CRUSE app was of 22 days (24.4% of 90 days).”
> “Our findings suggest that age, male sex, residence in Europe, and the use of monoclonal antibodies are significant factors associated with increased adherence to the CRUSE app.”

Source: [Viegas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619656/)

<a id="topic-2.2.2.4-10"></a>

### Quality-improvement study of guideline-based care: planned steps

> “Finally, some physicians are not aware of, or do not adhere to, international guidelines available for the treatment of CSU”
> “Step 3 (quality improvement): Recommendations to improve quality of care for patients with CSU will be developed, pilot tested, and published.”

Source: [Mosnaim et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12814061/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
